Birol Topçu

Dr. Birol Topçu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2014 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GEGamze Erfan
Gamze Erfan
SGSavas Guzel
Savas Guzel
SASeref Alpsoy
Seref Alpsoy
EREmine N. Rifaioglu
Emine N. Rifaioglu
SKSule Kaya
Sule Kaya
MKMustafa Kulac
Mustafa Kulac

12 January 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
AYAlpay Yeşilaltay
Alpay Yeşilaltay
DMDilek Muz
Dilek Muz
BEBerna ERDAL
Berna ERDAL
TBTürker Bilgen
Türker Bilgen
BBBahadır Batar
Bahadır Batar
BABurcu Altındağ Avcı
Burcu Altındağ Avcı
This study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, and bortezomib were used in MM cells. The cytotoxicity assay was investigated using WST-1. Apoptosis was assessed through flow cytometry with Annexin V/PI staining and caspase-9 concentrations using ELISA. To explore MYXV entry into MM cells, monoclonal antibodies were used. Moreover, to explore the mechanisms of MYXV entry into MM cells, we examined the level of GFP-labeled MYXV within the cells after blocking with monoclonal antibodies targeting BCMA, CD20, CD28, CD33, CD38, CD56, CD86, CD117, CD138, CD200, and CD307 in MM cells. The study demonstrated the effects of treating Myxoma virus with lenalidomide and bortezomib. The treatment resulted in reduced cell viability and increased caspase-9 expression. Only low-dose CD86 blockade showed a significant difference in MYXV entry into MM cells. The virus caused an increase in the rate of apoptosis in the cells, regardless of whether it was administered alone or in combination with drugs. The groups with the presence of the virus showed higher rates of early apoptosis. The Virus, Virus + Bortezomib, and Virus + Lenalidomide groups had significantly higher rates of early apoptosis (p < 0.001). However, the measurements of late apoptosis and necrosis showed variability. The addition of MYXV resulted in a statistically significant increase in early apoptosis in both newly diagnosed and refractory MM patients. Our results highlight that patient-based therapy should also be considered for the effective management of MM.

1 January 2016
Verified
Journal Article
Closed access
SESeyfi Emir
Seyfi Emir
SGSibel Ozkan Gurdal
Sibel Ozkan Gurdal
SSSelim Sozen
Selim Sozen
IBIlhan Bali
Ilhan Bali
EYEbru Yesildag
Ebru Yesildag
BTBirol Topçu
Birol Topçu

4 November 2014
Verified
Book Chapter
Closed access
PDF file
MYMehmet Yılmaz
Mehmet Yılmaz
NPNihan Potas
Nihan Potas
BTBirol Topçu
Birol Topçu

15 July 2014 in Electronic Journal of General Medicine
Verified
Journal Article
Open access
SASeref Alpsoy
Seref Alpsoy
AAAydın Akyuz
Aydın Akyuz
DADursun Cayan Akkoyun
Dursun Cayan Akkoyun
BNBurçin Nalbantoglu
Burçin Nalbantoglu
BTBirol Topçu
Birol Topçu
MDMustafa Metin Donma
Mustafa Metin Donma